BioSpace News Archive

Novavax and Serum Institute of India Private Limited (SIIPL) amended an agreement struck last month that will allow the company to double the number of doses of its experimental COVID-19 vaccine for potential use in 2021.

Novus Therapeutics announced on Monday that it had completed its acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company.

Transaction Supports NorthStar’s Growth in Core Markets and Surgery Partners’ Continued Focus on Its Core Short-Stay Surgical Business [15-September-2020] IRVING, Texas , Sept. 15, 2020 /PRNewswire/ -- NorthStar Anesthesia (“NorthStar” or the “Company”), one of the country’s leading anesthesia care providers and managers, today announced that Anesthesia Consulting

Minimizing the risk of infection for patients and staff is our top priority here at Gibson Diagnostic Labs. To effectively do so in the healthcare world requires facility readiness and workforce availability.

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, presented a poster at the TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference.

Physiotherapy also known as physical therapy is provided by physiotherapist to the patients suffering from disabilities and impairments of mobility.

Connected health also called as technology enabled care, involves the use of digital media, mobile devices, and health technology.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Dear Fellow Shareholders, This year, we saw the unprecedented need for the collaboration between industry and government in order to meet the challenge of the COVID-19 pandemic. Pluristem

Perseus Holdings USA, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, announced the appointment of Ben “Bud” M. Brigham to its board of directors, effective immediately.

- VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020. " Our OVAL trial of VB-111 in ovarian cancer continues to progress well, with over a third of the study participants already enrolled, " said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics.